Top

Published in:

01-03-2011

Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study

Authors: Mikkel Andreassen, Jens Faber, Andreas Kjær, Claus Leth Petersen, Lars Østergaard Kristensen

Published in: Pituitary | Issue 1/2011

Abstract

Assessed by conventional echocardiography the influence of growth hormone deficiency (GHD) and effects of replacement therapy on left ventricle (LV) function and mass (LVM) have shown inconsistent results. We aimed to evaluate cardiac function before and during replacement therapy employing the gold standard method cardiac magnetic resonance imaging (CMRI) and measurements of circulating levels of B-type natriuretic peptides. Sixteen patients (8 males and 8 females, mean age 49 years (range 18–75)) with severe GHD and 16 matched control subjects were included. CMRI was performed at baseline and after 1 year of GH replacement therapy. IGF-I, B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) were measured after 0, 1, 2, 3, 6 and 12 months of treatment. IGF-I Z-score increased from (median (IQR)) −2.3 (−3.8 to −1.4) to 0.5 (−0.3 to 1.7). LVM index (LVMI), ejection fraction (range 63–80%), cardiac output index and levels of BNP and NT-proBNP were similar at baseline in patients compared to controls (P-values from 0.09 to 0.37). The patients had significantly smaller LV end-diastolic volume index (P = 0.032) and end-systolic volume index (P = 0.038). No significant change in LV systolic function or LVM occurred during 1 year of GH treatment. BNP levels were unchanged (P = 0.88), whereas NT-proBNP tended to decrease (P = 0.052). Assessed by the highly sensitive and precise CMRI method, untreated GHD was not associated with impaired systolic function or reduced LVMI and 1 year of GH replacement using physiological doses did not influence cardiac mass or function.

Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288CrossRefPubMed

Bates AS, Van’t HW, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81:1169–1172CrossRefPubMed

Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001) Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group. Lancet 357:425–431CrossRefPubMed

Stochholm K, Laursen T, Green A, Laurberg P, Andersen M, Kristensen LO, Feldt-Rasmussen U, Christiansen JS, Frydenberg M, Gravholt CH (2008) Morbidity and GH deficiency: a nationwide study. Eur J Endocrinol 158:447–457CrossRefPubMed

Stochholm K, Gravholt CH, Laursen T, Laurberg P, Andersen M, Kristensen LO, Feldt-Rasmussen U, Christiansen JS, Frydenberg M, Green A (2007) Mortality and GH deficiency: a nationwide study. Eur J Endocrinol 157:9–18CrossRefPubMed

Cuneo RC, Salomon F, Wilmshurst P, Byrne C, Wiles CM, Hesp R, Sonksen PH (1991) Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci (Lond) 81:587–592

Amato G, Carella C, Fazio S, La MG, Cittadini A, Sabatini D, Marciano-Mone C, Sacca L, Bellastella A (1993) Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77:1671–1676CrossRefPubMed

Caidahl K, Eden S, Bengtsson BA (1994) Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) 40:393–400CrossRef

Beshyah SA, Shahi M, Skinner E, Sharp P, Foale R, Johnston DG (1994) Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 130:451–458CrossRefPubMed

10.

Thuesen L, Jorgensen JO, Muller JR, Kristensen BO, Skakkebaek NE, Vahl N, Christiansen JS (1994) Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol (Oxf) 41:615–620CrossRef

11.

Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I (1995) Cardiac performance and mass in adults with hypopituitarism: effects of 1 year of growth hormone treatment. J Clin Endocrinol Metab 80:659–666CrossRefPubMed

12.

Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasburger CJ (1995) Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 80:552–557CrossRefPubMed

13.

Sartorio A, Ferrero S, Conti A, Bragato R, Malfatto G, Leonetti G, Faglia G (1997) Adults with childhood-onset growth hormone deficiency: effects of growth hormone treatment on cardiac structure. J Intern Med 241:515–520CrossRefPubMed

14.

Ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA (1999) Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 84:2373–2380CrossRefPubMed

15.

Link K, Bulow B, Westman K, Salmonsson EC, Eskilsson J, Erfurth EM (2001) Low individualized growth hormone (GH) dose increased renal and cardiac growth in young adults with childhood onset GH deficiency. Clin Endocrinol (Oxf) 55:741–748CrossRef

16.

Gillberg P, Bramnert M, Thoren M, Werner S, Johannsson G (2001) Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm IGF Res 11:273–281CrossRefPubMed

17.

Colao A, Di SC, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G (2001) Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 86:1874–1881CrossRefPubMed

18.

Sneppen SB, Steensgaard-Hansen F, Feldt-Rasmussen U (2002) Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient adults. An 18 month randomised, placebo-controlled, double-blind study. Horm Res 58:21–29PubMed

19.

Ezzat S, Fear S, Gaillard RC, Gayle C, Landy H, Marcovitz S, Mattioni T, Nussey S, Rees A, Svanberg E (2002) Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 87:2725–2733CrossRefPubMed

20.

Pincelli AI, Bragato R, Scacchi M, Branzi G, Osculati G, Viarengo R, Leonetti G, Cavagnini F (2003) Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD). J Endocrinol Invest 26:420–428PubMed

21.

Feinberg MS, Scheinowitz M, Laron Z (2003) Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. Am Heart J 145:549–553CrossRefPubMed

22.

Erdogan D, Tukek T, Aral F, Oflaz H, Ozaydin M, Kocaman O, Akkaya V, Goren T, Molvalilar S (2004) Structural, functional and autonomic changes in the cardiovascular system in growth hormone deficient patients. Ann Noninvasive Electrocardiol 9:19–23CrossRefPubMed

23.

Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M, Bramnert M (2004) The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol (Oxf) 61:113–122CrossRef

24.

Minczykowski A, Gryczynska M, Ziemnicka K, Czepczynski R, Sowinski J, Wysocki H (2005) The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency. Growth Horm IGF Res 15:156–164CrossRefPubMed

25.

Colao A, Di SC, Cuocolo A, Spinelli L, Acampa W, Spiezia S, Rota F, Savanelli MC, Lombardi G (2005) Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. J Clin Endocrinol Metab 90:5146–5155CrossRefPubMed

26.

Climent VE, Pico A, Sogorb F, Aznar S, Lip GY, Marin F (2006) Growth hormone therapy and the heart. Am J Cardiol 97:1097–1102CrossRefPubMed

27.

Follin C, Thilen U, Ahren B, Erfurth EM (2006) Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after 2 years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab 91:1872–1875CrossRefPubMed

28.

Perez-Berbel P, Climent VE, Pico A, Marin F (2008) Short- and long-term effects of growth hormone on the heart. Int J Cardiol 124:393–394CrossRefPubMed

29.

Lazurova I, Pura M, Wagnerova H, Tajtakova M, Sedlakova M, Tomas L, Payer J, Hruzikova P, Vanuga P, Podoba J, Trejbalova L, Popovic V, Koltowska-Haggstrom M (2009) Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology and function in adults with growth hormone deficiency. Exp Clin Endocrinol Diabetes

30.

Cenci MC, Soares DV, Spina LD, de Lima Oliveira Brasil RR, Lobo PM, Mansur VA, Gold J, Michmacher E, Vaisman M, Conceicao FL (2009) Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary 12:322–329CrossRefPubMed

31.

Maison P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108:2648–2652CrossRefPubMed

32.

Ho KK (2007) Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the European society for pediatric endocrinology, lawson wilkins society, European society of endocrinology, Japan endocrine society, and endocrine society of Australia. Eur J Endocrinol 157:695–700CrossRefPubMed

33.

Hare JL, Brown JK, Marwick TH (2008) Performance of conventional echocardiographic parameters and myocardial measurements in the sequential evaluation of left ventricular function. Am J Cardiol 101:706–711CrossRefPubMed

34.

Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodelling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2:271–278CrossRefPubMed

35.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663CrossRefPubMed

36.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616CrossRefPubMed

37.

Weber M, Hamm C (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92:843–849CrossRefPubMed

38.

Munagala VK, Burnett JC Jr, Redfield MM (2004) The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 29:707–769CrossRefPubMed

39.

Longmore DB, Klipstein RH, Underwood SR, Firmin DN, Hounsfield GN, Watanabe M, Bland C, Fox K, Poole-Wilson PA, Rees RS (1985) Dimensional accuracy of magnetic resonance in studies of the heart. Lancet 1:1360–1362CrossRefPubMed

40.

Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21:1387–1396CrossRefPubMed

41.

Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK (2004) Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 25:1940–1965CrossRefPubMed

42.

Andersen M, Hansen TB, Støving RK, Bertelsen J, Hangaard J, Hyltoft Petersen P, Hagen C (2006) The pyridostigmine-growth-hormone-releasing-hormone in adults. The reference interval and a comparison with the insulin tolerance test

43.

Andreassen M, Nielsen K, Raymond I, Kristensen LO, Faber J (2009) Characteristics and reference ranges of insulin-like growth factor-I measured with a commercially available immunoassay in 724 healthy adult Caucasians. Scand J Clin Lab Invest 12:1–6CrossRef

44.

Lenstrup M, Kjaergaard J, Petersen CL, Kjaer A, Hassager C (2006) Evaluation of left ventricular mass measured by 3D echocardiography using magnetic resonance imaging as gold standard. Scand J Clin Lab Invest 66:647–657CrossRefPubMed

45.

Vogelsang TW, Jensen RJ, Monrad AL, Russ K, Olesen UH, Hesse B, Kjaer A (2007) Independent effects of both right and left ventricular function on plasma brain natriuretic peptide. Eur J Heart Fail 9:892–896CrossRefPubMed

46.

Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, Canham RM, Levine BD, Drazner MH (2006) Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas heart study. Circulation 113:1597–1604CrossRefPubMed

47.

Donath MY, Jenni R, Brunner HP, Anrig M, Kohli S, Glatz Y, Froesch ER (1996) Cardiovascular and metabolic effects of insulin-like growth factor I at rest and during exercise in humans. J Clin Endocrinol Metab 81:4089–4094CrossRefPubMed

48.

Cittadini A, Ishiguro Y, Stromer H, Spindler M, Moses AC, Clark R, Douglas PS, Ingwall JS, Morgan JP (1998) Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 83:50–59PubMed

49.

Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del RG, Boghen MF, Berti F, Muller EE, Ghigo E (1999) Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. Eur J Endocrinol 140:322–327CrossRefPubMed

50.

Sverrisdottir YB, Elam M, Herlitz H, Bengtsson BA, Johannsson G (1998) Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 83:1881–1885CrossRefPubMed

51.

Sverrisdottir YB, Elam M, Caidahl K, Soderling AS, Herlitz H, Johannsson G (2003) The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 21:1905–1914CrossRefPubMed

52.

Moller J (2003) Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 13:55–74CrossRefPubMed

53.

Slotwiner DJ, Devereux RB, Schwartz JE, Pickering TG, de Ray SG, Ganau A, Saba PS, Roman MJ (1998) Relation of age to left ventricular function in clinically normal adults. Am J Cardiol 82:621–626CrossRefPubMed

54.

de GC, Curto L, Recupero A, Grimaldi P, Almoto B, Venturino M, Cento D, Narbonne MC, Trimarchi F, Coglitore S, Cannavo S (2006) Echocardiographic assessment of subclinical left ventricular eccentric hypertrophy in adult-onset GHD patients by geometric remodelling: an observational case-control study. BMC Endocr Disord 6:1

55.

Filipsson H, Johannsson G (2009) GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 161(Suppl 1):S85–S95CrossRefPubMed

56.

Shimon I, Cohen O, Lubetsky A, Olchovsky D (2002) Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 12:823–827CrossRefPubMed

57.

Tomlinson JW, Stewart PM (2001) Cortisol metabolism and the role of 11 beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 15:61–78CrossRefPubMed

58.

Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112:2163–2168CrossRefPubMed

59.

Fernandes F, Ramires FJ, Buck PC, Almeida IJ, Rabelo R, Dantas SA, Salemi VM, Halpern A, Mady C (2007) N-terminal-pro-brain natriuretic peptide, but not brain natriuretic peptide, is increased in patients with severe obesity. Braz J Med Biol Res 40:153–158PubMed

60.

Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P, Koltowska-Haggstrom M (2006) Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur J Endocrinol 155:79–90CrossRefPubMed

61.

Franco C, Andersson B, Lonn L, Bengtsson BA, Svensson J, Johannsson G (2007) Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92:2644–2647CrossRefPubMed

62.

Colao A, Di SC, Spiezia S, Savastano S, Rota F, Savanelli MC, Lombardi G (2008) Growth hormone treatment on atherosclerosis: results of a 5 year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 93:3416–3424CrossRefPubMed

Title: Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study
Authors: Mikkel Andreassen
Jens Faber
Andreas Kjær
Claus Leth Petersen
Lars Østergaard Kristensen
Publication date: 01-03-2011
Publisher: Springer US
Published in: Pituitary / Issue 1/2011
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-010-0250-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Is left ventricular dysfunction reversed after treatment of active acromegaly?

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression

Effect of dopaminergic drug treatment on surgical findings in prolactinomas

Prevalence of hematological abnormalities in patients with Sheehan’s syndrome: response to replacement of glucocorticoids and thyroxine

On the shoulders of giants: Harvey Cushing’s experience with acromegaly and gigantism at the Johns Hopkins Hospital, 1896–1912

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page